10/19/2005 5:13:15 PM
NEWTON, Mass.--(BUSINESS WIRE)--April 11, 2005--Clinical Data, Inc. (NASDAQ:CLDA) announced today that it has entered into a worldwide distribution agreement with Daiichi Pure Chemicals Co., Ltd., of Tokyo for a diagnostic assay for the measurement of an extended range of high sensitivity C-Reactive Protein or "hsCRP". Daiichi's proprietary assay can be used on Clinical Data's existing line of clinical chemistry analyzers and on most conventional clinical chemistry systems currently in use.
The hsCRP assay, which will be distributed by Clinical Data under a non-exclusive worldwide agreement, is an in vitro diagnostic test for the quantitative determination of CRP in whole blood or serum. Measurement of CRP has been used increasingly by clinicians to aid in the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases.
comments powered by